Abstract
Several genetic, biochemical and pharmacological studies suggest that the cytosolic selenoprotein thioredoxin reductase 1 (TrxR1, TXNRD1) can serve as a promising anticancer drug target. This notion is in part based upon potent and selective targeting of the selenocysteine residue in TrxR1 by electrophilic anticancer agents. Whereas normal somatic cells typically can survive without TrxR1, the metabolic and proliferative realignments associated with cancer increase the oxidative stress and thus an increased reliance upon reducing pathways in cancer cells, thereby increasing their dependence upon TrxR1 activity. Intricate functional links between TrxR1 and transcription factors such as Nrf2, NF-kB and p53, and interaction with other growth-promoting signaling pathways, further underpin anticancer therapies involving TrxR1 targeting. However, caveats exist, as some effects of TrxR1 inhibition may promote cancer rather than counteract its progression. Although encouraging advances are being made, the field is clearly not yet ready for clinical trials evaluating novel specific TrxR1 inhibitors in anticancer treatments. In this chapter we present and discuss the major aspects of this topic.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
S Gromer et al 2004 Med Res Rev 24:40
J Nordberg, ES Arner 2001 Free Radic Biol Med 31:1287
K Becker et al 2000 Eur. J. Biochem. 267:6118
ES Arnér, A Holmgren 2000 Eur J Biochem 267:6102
ESJ Arnér 2009 Biochim Biophys Acta 1790:495
A Miranda-Vizuete et al 2004 Antioxid Redox Signal 6:25
JL Martin 1995 Structure 3:245
IS Harris et al 2015 Cancer Cell 27:211
C Cadenas et al 2010 Breast Cancer Res 12:R44
SS Singh et al 2008 Transl Oncol 1:153
MH Yoo et al 2007 PLoS One 2:e1112
MH Yoo et al 2006 J Biol Chem 281:13005
ESJ Arnér, A Holmgren 2006 Semin Cancer Biol 16:420
DT Lincoln et al 2003 Anticancer Res 23:2425
M Yamada et al 1996 Clin Cancer Res 2:427
XG Lei et al 2016 Physiol Rev 96:307
WO Osburn, TW Kensler 2008 Mutat Res 659:31
IM Copple et al 2008 Toxicology 246:24
DD Zhang 2006 Drug Metab Rev 38:769
KI Tong et al 2006 Biol Chem 387:1311
Y Mitsuishi et al 2012 Front Oncol 2:200
R Brigelius-Flohe, L Flohe 2011 Antioxid Redox Signal 15:2335
A Singh et al 2008 Cancer Res 68:7975
I Ganan-Gomez et al 2013 Free Radic Biol Med 65:750
D Mougiakakos et al 2012 J Mol Med (Berl) 90:935
S Ghosh et al 2015 Cell Signal 27:1398
C Zhao et al 2014 J Biol Chem 289:17020
M Cebula et al 2015 Antioxid Redox Signal 23:823
Q Cheng et al 2009 J Biol Chem 284:3998
S Prast-Nielsen et al 2011 Free Radic Biol Med 50:1114
Z Liu et al 2008 Biosci Biotechnol Biochem 72:2214
D Krishnamurthy et al 2008 J Med Chem 51:4790
CM Carvalho et al 2008 J Biol Chem 283:11913
AB Witte et al 2005 Free Radic Biol Med 39:696
Y Shi et al 2014 Cell Death Differ 21:612
X Peng et al 2013 Cell Death Dis 4:e881
W Cai et al 2012 Free Radic Biol Med 52:257
S Prast-Nielsen et al 2010 Free Radic Biol Med 49:1765
E Hedstrom et al 2009 Cell Cycle 8:3576
SE Eriksson et al 2009 Free Radic Biol Med 47:1661
X Wang et al 2008 Eur J Pharmacol 579:66
Z Liu et al 2008 Chem Biol Interact 177:48
EH Chew et al 2008 FASEB J 22:2072
A Casini et al 2008 J Med Chem 51:6773
C Marzano et al 2007 Free Radic Biol Med 42:872
J Lu et al 2007 Proc Natl Acad Sci U S A 104:12288
S Urig, K Becker 2006 Semin Cancer Biol 16:452
J Lu et al 2006 Cancer Res 66:4410
SI Hashemy et al 2006 J Biol Chem 281:10691
J Fang et al 2005 J Biol Chem 280:25284
P Wipf et al 2004 Org Biomol Chem 2:1651
SV Iverson et al 2013 Free Radic Biol Med 63:369
ML Locy et al 2012 Antioxid Redox Signal 17:1407
MF Rollins et al 2010 J Cell Sci 123:2402
KK Brown et al 2008 Free Radic Biol Med 45:494
Y Hu et al 2007 Biol Chem 388:1069
JR Bacon et al 2007 J Agric Food Chem 55:1170
J Jakubikova et al 2006 J Agric Food Chem 54:1656
SB Lee et al 2007 Biol Pharm Bull 30:1074
RL Poerschke et al 2012 J Biochem Mol Toxicol 26:344
LG Higgins, JD Hayes 2011 Chem Biol Interact 192:37
EH Chew et al 2010 Free Radic Biol Med 48:98
YJ Surh et al 2008 Planta Med 74:1526
R Brigelius-Flohé 2008 Chem Biodivers 5:389
R Brigelius-Flohé, A Banning 2006 Free Radic Res 40:775
G Manda et al 2015 Redox Biol 5:347
L Galluzzi et al 2013 Nat Rev Drug Discov 12:829
J Luo et al 2009 Cell 136:823
D Trachootham et al 2009 Nat Rev Drug Discov 8:579
D Trachootham et al 2006 Cancer Cell 10:241
DL Hatfield et al 2009 Biochim Biophys Acta 1790:1541
PK Mandal et al 2010 Cancer Res 70:9505
K AnestĂ¥l et al 2008 PLoS One 3:e1846
K AnestĂ¥l, ESJ ArnĂ©r 2003 J Biol Chem 278:15966
S Brnjic et al 2014 Antioxid Redox Signal 21:2271
L Bonfili et al 2012 ChemMedChem 7:2010
S Qiao et al 2012 Biochem Pharmacol 83:1229
EE Fink et al 2015 Leukemia 30:104
X Wang et al 2014 Mol Pharmacol 85:932
A Casini, L Messori 2011 Curr Top Med Chem 11:2647
C Gabbiani, L Messori 2011 Anticancer Agents Med Chem 11:929
F Kriegenburg et al 2011 Antioxid Redox Signal 15:2265
F Shan et al 2015 Cancer Lett doi:10.1016/j.canlet.2015.12.023
KE Craven et al 2015 Cancer Lett doi:10.1016/j.canlet.2015.11.047
SC Casey et al 2015 Semin Cancer Biol 35(Suppl):S199
Z Wang et al 2015 Semin Cancer Biol 35(Suppl):S224
J Hellfritsch et al 2015 Antioxid Redox Signal 22:938
MF He et al 2014 Eur J Pharmacol 740:240
I Ott et al 2009 J Med Chem 52:763
T Zou et al 2014 Angew Chem Int Ed Engl 53:5810
MA Abdelsaid et al 2013 Antioxid Redox Signal 19:2199
KL Streicher et al 2004 Nutr Cancer 50:221
B Ruffell, LM Coussens 2015 Cancer Cell 27:462
DS Vinay et al 2015 Semin Cancer Biol 35(Suppl):S185
V Shahabi et al 2015 Am J Clin Oncol 38:90
E Backman et al 2007 Haematologica 92:1495
K Hori et al 1993 Journal of Immunology 151:5624
K Pekkari et al 2005 Blood 105:1598
K Pekkari, A Holmgren 2004 Antioxid Redox Signal 6:53
A Maillet, S Pervaiz 2011 Antioxid Redox Signal 16:1285
PB Cassidy et al 2006 Carcinogenesis 27:2538
MK Yu et al 2004 J Biol Chem 279:28028
PJ Moos et al 2003 J Biol Chem 278:745
N Turunen et al 2004 APMIS 112:123
X Ma et al 2002 J Biol Chem 277:22460
J Hu et al 2001 Oncogene 20:4235
MA Feitelson et al 2015 Semin Cancer Biol 35(Suppl):S25
ML Megison et al 2013 Anticancer Agents Med Chem 13:563
M Dagnell et al 2013 Proc Natl Acad Sci U S A 110:13398
A Ostman et al 2011 J Biochem 150:345
SH Cho et al 2004 FEBS Lett 560:7
K Johansson et al 2015 Antioxid Redox Signal doi:10.1089/ars.2015.6419
BL Probst et al 2015 PLoS One 10:e0135257
C Gorrini et al 2013 J Exp Med 210:1529
G Filomeni et al 2012 Biochem Pharmacol 83:1349
Acknowledgements
Work of the authors has support from The National Institute of Health (NIH), Swedish Cancer Society, Swedish Research Council (Medicine and Natural Sciences sections), The Wenner-Gren Foundations, Knut and Alice Wallenberg Foundation, Montana State University and Karolinska Institutet.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Schmidt, E.E., Arnér, E.S.J. (2016). Thioredoxin Reductase 1 as an Anticancer Drug Target. In: Hatfield, D., Schweizer, U., Tsuji, P., Gladyshev, V. (eds) Selenium. Springer, Cham. https://doi.org/10.1007/978-3-319-41283-2_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-41283-2_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41281-8
Online ISBN: 978-3-319-41283-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)